Randomized, Multicenter, Phase II Study of CO-101 Versus Gemcitabine in Patients With Metastatic Pancreatic Ductal Adenocarcinoma: Including a Prospective Evaluation of the Role of hENT1 in Gemcitabine or CO-101 Sensitivity.

Research output: Contribution to journalArticle

Standard

Randomized, Multicenter, Phase II Study of CO-101 Versus Gemcitabine in Patients With Metastatic Pancreatic Ductal Adenocarcinoma: Including a Prospective Evaluation of the Role of hENT1 in Gemcitabine or CO-101 Sensitivity. / Poplin, Elizabeth; Wasan, Harpreet; Rolfe, Lindsey; Raponi, Mitch; Ikdahl, Tone; Bondarenko, Ihor; Davidenko, Irina; Bondar, Volodymyr; Garin, August; Boeck, Stefan; Ormanns, Steffen; Heinemann, Volker; Bassi, Claudio; Evans, T R Jeffrey; Andersson, Roland; Hahn, Hejin; Picozzi, Vince; Dicker, Adam; Mann, Elaina; Voong, Cynthia; Kaur, Paramjit; Isaacson, Jeff; Allen, Andrew.

In: Journal of Clinical Oncology, Vol. 31, No. 35, 2013, p. 4453-4461.

Research output: Contribution to journalArticle

Harvard

Poplin, E, Wasan, H, Rolfe, L, Raponi, M, Ikdahl, T, Bondarenko, I, Davidenko, I, Bondar, V, Garin, A, Boeck, S, Ormanns, S, Heinemann, V, Bassi, C, Evans, TRJ, Andersson, R, Hahn, H, Picozzi, V, Dicker, A, Mann, E, Voong, C, Kaur, P, Isaacson, J & Allen, A 2013, 'Randomized, Multicenter, Phase II Study of CO-101 Versus Gemcitabine in Patients With Metastatic Pancreatic Ductal Adenocarcinoma: Including a Prospective Evaluation of the Role of hENT1 in Gemcitabine or CO-101 Sensitivity.', Journal of Clinical Oncology, vol. 31, no. 35, pp. 4453-4461. https://doi.org/10.1200/JCO.2013.51.0826

APA

CBE

Poplin E, Wasan H, Rolfe L, Raponi M, Ikdahl T, Bondarenko I, Davidenko I, Bondar V, Garin A, Boeck S, Ormanns S, Heinemann V, Bassi C, Evans TRJ, Andersson R, Hahn H, Picozzi V, Dicker A, Mann E, Voong C, Kaur P, Isaacson J, Allen A. 2013. Randomized, Multicenter, Phase II Study of CO-101 Versus Gemcitabine in Patients With Metastatic Pancreatic Ductal Adenocarcinoma: Including a Prospective Evaluation of the Role of hENT1 in Gemcitabine or CO-101 Sensitivity. Journal of Clinical Oncology. 31(35):4453-4461. https://doi.org/10.1200/JCO.2013.51.0826

MLA

Vancouver

Author

Poplin, Elizabeth ; Wasan, Harpreet ; Rolfe, Lindsey ; Raponi, Mitch ; Ikdahl, Tone ; Bondarenko, Ihor ; Davidenko, Irina ; Bondar, Volodymyr ; Garin, August ; Boeck, Stefan ; Ormanns, Steffen ; Heinemann, Volker ; Bassi, Claudio ; Evans, T R Jeffrey ; Andersson, Roland ; Hahn, Hejin ; Picozzi, Vince ; Dicker, Adam ; Mann, Elaina ; Voong, Cynthia ; Kaur, Paramjit ; Isaacson, Jeff ; Allen, Andrew. / Randomized, Multicenter, Phase II Study of CO-101 Versus Gemcitabine in Patients With Metastatic Pancreatic Ductal Adenocarcinoma: Including a Prospective Evaluation of the Role of hENT1 in Gemcitabine or CO-101 Sensitivity. In: Journal of Clinical Oncology. 2013 ; Vol. 31, No. 35. pp. 4453-4461.

RIS

TY - JOUR

T1 - Randomized, Multicenter, Phase II Study of CO-101 Versus Gemcitabine in Patients With Metastatic Pancreatic Ductal Adenocarcinoma: Including a Prospective Evaluation of the Role of hENT1 in Gemcitabine or CO-101 Sensitivity.

AU - Poplin, Elizabeth

AU - Wasan, Harpreet

AU - Rolfe, Lindsey

AU - Raponi, Mitch

AU - Ikdahl, Tone

AU - Bondarenko, Ihor

AU - Davidenko, Irina

AU - Bondar, Volodymyr

AU - Garin, August

AU - Boeck, Stefan

AU - Ormanns, Steffen

AU - Heinemann, Volker

AU - Bassi, Claudio

AU - Evans, T R Jeffrey

AU - Andersson, Roland

AU - Hahn, Hejin

AU - Picozzi, Vince

AU - Dicker, Adam

AU - Mann, Elaina

AU - Voong, Cynthia

AU - Kaur, Paramjit

AU - Isaacson, Jeff

AU - Allen, Andrew

PY - 2013

Y1 - 2013

N2 - Gemcitabine requires transporter proteins to cross cell membranes. Low expression of human equilibrative nucleoside transporter-1 (hENT1) may result in gemcitabine resistance in pancreatic ductal adenocarcinoma (PDAC). CO-101, a lipid-drug conjugate of gemcitabine, was rationally designed to enter cells independently of hENT1. We conducted a randomized controlled trial to determine whether CO-101 improved survival versus gemcitabine in patients with metastatic PDAC (mPDAC) with low hENT1. The study also tested the hypothesis that gemcitabine is more active in patients with mPDAC tumors with high versus low hENT1 expression.

AB - Gemcitabine requires transporter proteins to cross cell membranes. Low expression of human equilibrative nucleoside transporter-1 (hENT1) may result in gemcitabine resistance in pancreatic ductal adenocarcinoma (PDAC). CO-101, a lipid-drug conjugate of gemcitabine, was rationally designed to enter cells independently of hENT1. We conducted a randomized controlled trial to determine whether CO-101 improved survival versus gemcitabine in patients with metastatic PDAC (mPDAC) with low hENT1. The study also tested the hypothesis that gemcitabine is more active in patients with mPDAC tumors with high versus low hENT1 expression.

U2 - 10.1200/JCO.2013.51.0826

DO - 10.1200/JCO.2013.51.0826

M3 - Article

VL - 31

SP - 4453

EP - 4461

JO - Journal of clinical oncology : official journal of the American Society of Clinical Oncology

T2 - Journal of clinical oncology : official journal of the American Society of Clinical Oncology

JF - Journal of clinical oncology : official journal of the American Society of Clinical Oncology

SN - 1527-7755

IS - 35

ER -